3 US Penny Stocks To Consider In February 2025

As of February 2025, U.S. markets have been experiencing a mixed performance, with the S&P 500 and Nasdaq falling for the fourth consecutive day amid concerns about economic outlook and policy impacts. Despite these challenges, investors often look to penny stocks as a potential area for growth due to their affordability and the unique opportunities they present. While once considered speculative, penny stocks can still offer compelling prospects when backed by strong financials, making them worth considering for those seeking under-the-radar investment opportunities.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$123.69M	★★★★★★
BAB (OTCPK:BABB)	$0.8998	$6.27M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.90	$395.93M	★★★★☆☆
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
North European Oil Royalty Trust (NYSE:NRT)	$4.55	$41.08M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.58	$78.86M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.44	$46.86M	★★★★★★
PHX Minerals (NYSE:PHX)	$4.11	$149.92M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.32	$24.12M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8239	$76.37M	★★★★★☆

Click here to see the full list of 735 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Cheche Group (NasdaqCM:CCG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Cheche Group Inc. operates an auto insurance technology platform and has a market cap of $89.52 million.

Operations: The company generates revenue primarily from its Insurance Brokers segment, which accounted for CN¥3.36 billion.

Market Cap: $89.52M

Cheche Group Inc., with a market cap of US$89.52 million, operates in the auto insurance technology sector and primarily generates revenue from its Insurance Brokers segment, totaling CN¥3.36 billion. Recent earnings reports show a positive trend, with third-quarter sales rising to CN¥850.52 million and a net income of CN¥4.05 million compared to losses previously reported. The company has more cash than total debt, providing financial stability despite being unprofitable currently. Cheche's short-term assets exceed both its short- and long-term liabilities, indicating strong liquidity management amidst an evolving board and management team structure.

• Click here and access our complete financial health analysis report to understand the dynamics of Cheche Group.
• Gain insights into Cheche Group's outlook and expected performance with our report on the company's earnings estimates.

Telomir Pharmaceuticals (NasdaqCM:TELO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Telomir Pharmaceuticals, Inc. is a pre-clinical stage biopharmaceutical company dedicated to developing pharmaceutical products aimed at reversing oxidative stress and enhancing cellular protection, with a market cap of approximately $126.19 million.

Operations: Telomir Pharmaceuticals, Inc. does not report any revenue segments as it is currently in the pre-clinical stage of its development.

Market Cap: $126.19M

Telomir Pharmaceuticals, Inc., with a market cap of approximately US$126.19 million, remains pre-revenue as it advances its preclinical stage biopharmaceutical developments. Recent breakthroughs include the stabilization of Silver(II) in Telomir-1, offering potential for advanced antimicrobial treatments and wound care solutions. Despite its innovative strides, the company faces financial challenges; it reported a net loss of US$16.53 million for 2024 and auditors have expressed doubts about its ability to continue as a going concern. However, Telomir has raised additional capital through equity offerings to support ongoing research initiatives in areas like AMD and progeria.

• Take a closer look at Telomir Pharmaceuticals' potential here in our financial health report.
• Examine Telomir Pharmaceuticals' earnings growth report to understand how analysts expect it to perform.

PMV Pharmaceuticals (NasdaqGS:PMVP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule and tumor-agnostic therapies targeting p53 mutations in cancer, with a market cap of $73.99 million.

Operations: PMV Pharmaceuticals, Inc. does not report any specific revenue segments.

Market Cap: $74M

PMV Pharmaceuticals, with a market cap of US$73.99 million, is pre-revenue and focused on precision oncology targeting p53 mutations. The company has no debt and sufficient cash runway for over three years if free cash flow remains stable. Despite its current unprofitability and increased losses over the past five years, analysts predict a significant stock price increase of 305.6%. Recent activities include presenting at healthcare conferences and filing a shelf registration for US$3.71 million in common stock offerings to potentially bolster its financial position amidst ongoing development efforts.

• Jump into the full analysis health report here for a deeper understanding of PMV Pharmaceuticals.
• Gain insights into PMV Pharmaceuticals' future direction by reviewing our growth report.

Turning Ideas Into Actions

• Unlock more gems! Our US Penny Stocks screener has unearthed 732 more companies for you to explore.Click here to unveil our expertly curated list of 735 US Penny Stocks.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com